Cell Therapy for Autoimmune Disease Summit

Amidst the transformative impact of CAR-T and other cell therapies in cancer treatment, there is an electrifying sense of anticipation for their immense potential in indications beyond oncology. With compelling clinical results demonstrated in lupus, multiple sclerosis, pemphigus vulgaris, and many other autoimmune diseases, a wave of optimism surges forward. Moreover, the FDA’s rapid issuance of IND approvals and fast-track designations adds to the momentum of this groundbreaking approach, underscoring its potential to revolutionize the lives of millions affected by chronic autoimmune diseases worldwide.

Enter the inaugural Cell Therapy for Autoimmune Disease Summit, a pioneering platform singularly focused on uniting and empowering this community for the first time. Here, experts delve into cutting-edge frontiers of pre-clinical, translational, and clinical advancements encompassing all cell-based therapies, including CAR-T, Treg, and MSC, with the shared objective of developing better therapies for patients with chronic autoimmune diseases.

Tickets https://go.evvnt.com/1834740-2?pid=10018
Brochure https://go.evvnt.com/1834740-3?pid=10018

Prices:
Industry | Conference + Workshop Day USD 4297.00
Industry | Conference Only USD 2999.00
Academic Pricing | Conference + Workshop Day USD 3697.00
Academic Pricing | Conference Only USD 2599.00
Solution Providers | Conference + Workshop Day USD 5297.00
Solution Providers | Conference Only USD 3799.00

Speakers: Adel Nada | Co-Founder & Chief Executive Officer | GentiBio, AJ Joshi | Chief Medical Officer | Atara Biotherapeutics Inc., Amit Bar-Or | Director, Center for Neuroinflammation & Experimental Therapeutics & Chief, Multiple Sclerosis Division | University of Pennsylvania, David Porter | Director, Cell Therapy & Transplant | University of Pennsylvania, Dorota Iwaszkiewicz- Grzes | Chief Scientific Officer | PolTREG, Ellen Cahir-McFarland | Chief Scientific Officer | Abata Therapeutics, Greg Deener | Chief Executive Officer | iCell Gene Therapeutics, Haig Aghajanian | Co-Founder & Vice President, Research | Capstan Therapeutics, James Chung | Chief Medical Officer | Kyverna Therapeutics, James Li | Co-Founder, Chairman & Chief Executive Officer | JW Therapeutics, Jeff Liter | President & Chief Executive Officer | Luminary Therapeutics, Jenny McGovern | Director - Non-Clinical Group Leader | Quell Therapeutics, Jim Riley | Professor, Department of Microbiology | University of Pennsylvania, Jinmin Lee | Head of Cellular & Molecular Immunology | Cabaletta Bio, Marko Radic | Associate Professor, Department of Microbiology, Immunology & Biochemistry | The University of Tennessee Health Science Center, Milos Miljkovic | Chief Medical Officer | Cartesian Therapeutics, Peter Gergely | Executive Director & Head of Rheumatology | Novartis Institutes for BioMedical Research, Peter Merkel | Chief, Division of Rheumatology & Professor, Medicine & Epidemiology | University of Pennsylvania, Phil Johnson | Chief Executive Officer | Interius BioTherapeutics, Piotr Trzonkowski | Chief Executive Officer | PolTREG, Samik Basu | Chief Scientific Officer | Cabaletta Bio, Samuel Zhang | Chief Business Officer | Gracell Biotechnologies, Silviu Itescu | Chief Executive Officer | Mesoblast, Tatiana Ort | Head of Bioscience, Immunology | AstraZeneca, Tiffany Chen | Vice President, Discovery | GentiBio, Tom Van Blarcom | Senior Vice President & Head of Research | Kyverna Therapeutics, Tracey Lodie | Chief Scientific Officer | Quell Therapeutics, Wanjun Chen | Senior Investigator, Chief, Mucosal Immunology Section | National Institute of Health